Results 201 to 210 of about 20,698 (251)

Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Type 1 diabetes is defined by immune‐mediated beta‐cell failure and dependence on exogenous insulin. That definition is correct, but it may not fully describe many people seen in current clinical practice. Overweight and obesity are now common in type 1 diabetes, leading to variable combinations of high insulin requirement, hypertension ...
Zachary Bloomgarden
wiley   +1 more source

Efficacy and Safety of Semaglutide in Patients with Polycystic Ovary Syndrome: A Scoping Review. [PDF]

Biomedicines
La Vignera S, Condorelli RA.
europepmc   +1 more source

Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology. [PDF]

Front Cardiovasc Med
Li M.
europepmc   +1 more source

Cognitive signs and symptoms in people with a psychiatric diagnosis on semaglutide: a retrospective cohort study of 13 007 patients in the USA. [PDF]

BMJ Ment Health
De Giorgi R, Lipunova N, Mathias E, Shang F, Taquet M.   +4 more
europepmc   +1 more source

Defining Weight‐Loss‐Independent Hepatic Effects of Incretin‐Based Therapies

Diabetes, Obesity and Metabolism, EarlyView.
Mingyuan Zhang, Hanyang Liu, Yawen Hao, Lanlan Chen   +3 more
wiley   +1 more source

Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?

Journal of Internal Medicine, EarlyView.
Abstract Hypocholesterolemia is perceived as benign given its association with lower cardiovascular risk. However, genetic and epidemiological evidence indicates that persistently low levels of low‐density lipoprotein cholesterol (LDL‐C) and apolipoprotein B (ApoB) arise from distinct biological mechanisms with different hepatic implications ...
Valentina Flagiello, Emelie Barreby, Umberto Vespasiani‐Gentilucci, Stefano Romeo   +3 more
wiley   +1 more source

Comparative Efficacy of Semaglutide and Tirzepatide in Chinese Adults with Obesity without Diabetes: A Real-World Observational Study. [PDF]

Diabetes Metab Syndr Obes
Yao Z, Ahmad A, Gong F, Zhang N, Zeng M, Ge Q.   +5 more
europepmc   +1 more source

Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk

Journal of Internal Medicine, EarlyView.
Abstract Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome, affects 10%–13% of women of reproductive age and remains underdiagnosed despite its substantial health burden. The introduction of the new PMOS nomenclature in 2026 reflects a fundamental shift in understanding the condition as a lifelong endocrine ...
Maria Forslund, Johanna Melin, Anju E. Joham, Terhi T. Piltonen, D. Aled Rees, Helena J. Teede   +5 more
wiley   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source